Chimerix股票讨论区

$Chimerix(CMRX.US)$ ONC206 is a second generation ClpP agonist and DRD2 antagonist that has demonstrated monotherapy anti-cancer activity in pre-clinical models in primary CNS tumors and solid tumors outside of the CNS.
Phase I dose escalation trials continue at the National Institutes of Health (NIH) and the Pacific Pediatric Neuro-Oncology Consortium (PNOC) in adult and pediatric CNS tumor patients, respectively. The dose escalation trials are currently dosing at a...

$Chimerix(CMRX.US)$ Strong Buy Rating for Chimerix on Robust Financials and Promising Drug Pipeline

$Chimerix(CMRX.US)$ 机构在吸码。

$Chimerix(CMRX.US)$ 内部人士在增持，感觉有好消息要来了。最近医药股很妖

$Chimerix(CMRX.US)$  狂飙的前奏：先抑后扬

$Chimerix(CMRX.US)$
This is all I need to hold and/or buy more on dips
"..Turning to clinical outcomes. The survival of H3 K27-mutant glioma patients who received ONC201 in the frontline setting following radiotherapy, which I'll notice the same setting of the ACTION trial was reported as 21.7 months from diagnosis in contrast to 12 months for patients who did not receive ONC201. Favorable survival outcomes among ONC201 treated patients were consistently observed across a variety of sensitivity ...

$Chimerix(CMRX.US)$ 大力建仓
德開始報道於 Chimerix Inc （納斯達克股票代碼：CMRX）的評級爲 “跑贏大盤”。Chimerix的目標價格定爲7.00美元。Chimerix在第一季度的收入爲0.24美元，而去年同期爲0.28美元。目前，該股創下52周高點2.89美元，創52周低點1.09美元。Chimerix在上一個交易期結束時收於1.40美元。